-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tivozanib Hydrochloride in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tivozanib Hydrochloride in Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tivozanib Hydrochloride in Prostate Cancer Drug Details: Tivozanib Hydrochloride (Fotivda) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tivozanib Hydrochloride in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tivozanib Hydrochloride in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tivozanib Hydrochloride in Pancreatic Cancer Drug Details: Tivozanib Hydrochloride (Fotivda) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tivozanib Hydrochloride in Gallbladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tivozanib Hydrochloride in Gallbladder Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tivozanib Hydrochloride in Gallbladder Cancer Drug Details: Tivozanib Hydrochloride (Fotivda) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tivozanib Hydrochloride in Soft Tissue Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tivozanib Hydrochloride in Soft Tissue Sarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tivozanib Hydrochloride in Soft Tissue Sarcoma Drug Details: Tivozanib Hydrochloride...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tivozanib Hydrochloride in Neuroendocrine Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tivozanib Hydrochloride in Neuroendocrine Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tivozanib Hydrochloride in Neuroendocrine Cancer Drug Details: Tivozanib Hydrochloride (Fotivda) is...
-
Company Insights
Innovation and Patenting activity of AVEO Pharmaceuticals Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of AVEO Pharmaceuticals Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tipifarnib in Transitional Cell Cancer (Urothelial Cell Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tipifarnib in Transitional Cell Cancer (Urothelial Cell Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tipifarnib in Transitional Cell Cancer (Urothelial Cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CDX-301 in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CDX-301 in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CDX-301 in Metastatic Breast Cancer Drug Details: CDX-301 is under development...
-
Product Insights
NewPeritoneal Tumor – Drugs In Development, 2024
Empower your strategies with our Peritoneal Tumor – Drugs In Development, 2024 report and make more profitable business decisions. Peritoneal tumor is the invasion of the serous membrane lining the peritoneal cavity by malignant cells, that lines the inside wall of the abdomen and covers the uterus and extends over the bladder and rectum. The malignant cells originate de novo in the mesothelioma or disseminate from other primary tumor sites. The Peritoneal Tumor drugs in development market research report provide comprehensive...
-
Product Insights
NewPancreatic Tumor – Drugs In Development, 2024
Empower your strategies with our Pancreatic Tumor – Drugs In Development, 2024 report and make more profitable business decisions. Pancreatic cancer refers to the carcinoma arising from the pancreatic duct cells. Small changes in the cellular DNA result in uncontrolled multiplication and accumulation of cells into a tumor. Signs and symptoms of the most common form of pancreatic cancer may include yellow skin, abdominal or back pain, unexplained weight loss, light-colored stools, dark urine, and loss of appetite. Surgical resection is...